The Potential Role of Genomic Signature in Stage II Relapsed Colorectal Cancer (CRC) Patients: A Mono-Institutional Study

References

• Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal-tumor development. N Engl J Med. 1988;319:525–532. doi:10.1056/NEJM198809013190901
   PubMed Web of Science ®Google Scholar
• Dinu D, Dobre M, Panaitescu E, et al. Prognostic significance of KRAS gene mutations in colorectal cancer–preliminary study. J Med Life. 2014;7(4):581–587.
   PubMedGoogle Scholar
• Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949–954. doi:10.1038/nature00766
   PubMed Web of Science ®Google Scholar
• Cathomas G. PIK3CA in Colorectal Cancer. Front Oncol. 2014;4:35. doi:10.3389/fonc.2014.00035
   PubMedGoogle Scholar
• Soussi T, Béroud C. Significance of TP53 mutations in human cancer: a critical analysis of mutations at CpG dinucleotides. Hum Mutat. 2003;21(3):192–200. doi:10.1002/humu.10189
   PubMed Web of Science ®Google Scholar
• Smith G, Carey FA, Beattie J, et al. Mutations in APC, Kirsten-ras, and p53–alternative genetic pathways to colorectal cancer. Proc Natl Acad Sci U S A. 2002;99(14):9433–9438.
   PubMed Web of Science ®Google Scholar
• Therkildsen C, Bergmann TK, Henrichsen-Schnack T, Ladelund S, Nilbert M. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: a systematic review and meta-analysis. Acta Oncol. 2014;53(7):852–864. doi:10.3109/0284186X.2014.895036
   PubMed Web of Science ®Google Scholar
• Sargent D, Sobrero A, Grothey A, et al. Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol. 2009;27(6):872–877. doi:10.1200/JCO.2008.19.5362
   PubMed Web of Science ®Google Scholar
• Longley DB, Harkin DP, Johnston PG. 5-Fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer. 2003;3(5):330–338. doi:10.1038/nrc1074
   PubMed Web of Science ®Google Scholar
• Benson AB, Schrag D, Somerfield MR, et al. American society of clinical oncology recommendations on adjuvant chemotherapy for Stage II colon cancer. J Clin Oncol. 2004;22(16):3408–3419. doi:10.1200/JCO.2004.05.063
   PubMed Web of Science ®Google Scholar
• Köhne CH. Should adjuvant chemotherapy become standard treatment for patients with Stage II colon cancer? Against the proposal. Lancet Oncol. 2006;7(6):516–517.
   PubMed Web of Science ®Google Scholar
• Sobrero A, Köhne CH. Should adjuvant chemotherapy become standard treatment for patients with Stage II colon cancer? Lancet Oncol. 2006;7(6):515–516. doi:10.1016/S1470-2045(06)70727-6
   PubMed Web of Science ®Google Scholar
• Hutchins G, Southward K, Handley K, et al. Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. J Clin Oncol. 2011;29(10):1261–1270. doi:10.1200/JCO.2010.30.1366
   PubMed Web of Science ®Google Scholar
• Sinicrope FA, Mahoney MR, Yoon HH, et al. Analysis of molecular markers by anatomic tumor site in Stage III colon carcinomas from adjuvant chemotherapy trial NCCTG N0147 (Alliance). Clin Cancer Res. 2015;21(23):5294–5304. doi:10.1158/1078-0432.CCR-15-0527
   PubMed Web of Science ®Google Scholar
• Sinicrope FA, Mahoney MR, Smyrk TC, et al. Prognostic impact of deficient DNA mismatch repair in patients with Stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy. I J Clin Oncol. 2013;31(29):3664–3672. doi:10.1200/JCO.2013.48.9591
   Google Scholar
• Taieb J, Le Malicot K, Shi Q, et al. Prognostic value of BRAF and KRAS mutations in MSI and MSS Stage III colon cancer. J Natl Cancer Inst. 2016;109(5):djw272. doi:10.1093/jnci/djw272
   PubMedGoogle Scholar
• He Y, Van’t Veer LJ, Mikolajewska-Hanclich I, et al. PIK3CA mutations predict local recurrences in rectal cancer patients. Clin Cancer Res. 2009;15(22):6956–6962. doi:10.1158/1078-0432.CCR-09-1165
   PubMed Web of Science ®Google Scholar
• Oh HJ, Bae JM, Wen X, et al. P53 expression status is associated with cancer-specific survival in Stage III and high-risk Stage II colorectal cancer patients treated with oxaliplatin-based adjuvant chemotherapy. Br J Cancer. 2019;120(8):797–805. doi:10.1038/s41416-019-0429-2
   PubMed Web of Science ®Google Scholar
• Zaanan A, Cuilliere-Dartigues P, Guilloux A, et al. Impact of P53 expression and microsatellite instability on Stage III colon cancer disease-free survival in patients treated by 5-Fluorouracil and leucovorin with or without oxaliplatin. Ann Oncol. 2010;21(4):772–780. doi:10.1093/annonc/mdp383
   PubMed Web of Science ®Google Scholar
• Ntavatzikos A, Spathis A, Patapis P, et al. TYMS/KRAS/BRAF molecular profiling predicts survival following adjuvant chemotherapy in colorectal cancer. World J Gastrointest Oncol. 2019;11(7):551–566. doi:10.4251/wjgo.v11.i7.551
   PubMed Web of Science ®Google Scholar
• Uchida K, Hayashi K, Kawakami K, et al. Loss of heterozygosity at the thymidylate synthase (TS) locus on chromosome 18 affects tumor response and survival in individuals heterozygous for a 28-bp polymorphism in the TS gene. Clin Cancer Res. 2004;10(2):433–439. doi:10.1158/1078-0432.CCR-0200-03
   PubMed Web of Science ®Google Scholar
• Van den Broek E, Krijgsman O, Sie D, et al. Genomic profiling of stage II and III colon cancers reveals APC mutations to be associated with survival in Stage III colon cancer patients. Oncotarget. 2016;7(45):73876–73887. doi:10.18632/oncotarget.12510
   PubMedGoogle Scholar
• Henriksson ML, Edin S, Dahlin AM, et al. Colorectal cancer cells activate adjacent fibroblasts resulting in FGF1/FGFR3 signaling and increased invasion. Am J Pathol. 2011;178(3):1387–1394. doi:10.1016/j.ajpath.2010.12.008
   PubMed Web of Science ®Google Scholar
• Takayama T, Miyanishi K, Hayashi T, Sato Y, Niitsu Y. Colorectal cancer: genetics of development and metastasis. J Gastroenterol. 2006;41(3):185–192. doi:10.1007/s00535-006-1801-6
   PubMed Web of Science ®Google Scholar
• Day FL, Jorissen RN, Lipton L, et al. PIK3CA and PTEN gene and exon mutation-specific clinicopathologic and molecular associations in colorectal cancer. Clin Cancer Res. 2013;19(12):3285–3296. doi:10.1158/1078-0432.CCR-12-3614
   PubMed Web of Science ®Google Scholar
• Chung Y, Wi YC, Kim Y, et al. The Smad4/PTEN expression pattern predicts clinical outcomes in colorectal adenocarcinoma. J Pathol Transl Med. 2018;52(1):37–44. doi:10.4132/jptm.2017.10.20
   PubMed Web of Science ®Google Scholar
• Danielsen SA, Eide PW, Nesbakken A, et al. Portrait of the PI3K/AKT pathway in colorectal cancer. Biochimica Et Biophysica Acta - Rev Cancer. 2015;1855:104–121.
   PubMed Web of Science ®Google Scholar
• Johnson SM, Gulhati P, Rampy BA, et al. Novel expression patterns of PI3K/Akt/MTOR signaling pathway components in colorectal cancer. J Am Coll Surg. 2010;210(5):767–76, 776–8. doi:10.1016/j.jamcollsurg.2009.12.008
   Web of Science ®Google Scholar
• Cerami E, Gao J, Dogrusoz U, et al. The cbio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2(5):401–404. doi:10.1158/2159-8290.CD-12-0095
   PubMed Web of Science ®Google Scholar
• Gao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis of complex cancer genomics and clinical profiles using the CBioPortal. Sci Signal. 2013;6(269):pl1. doi:10.1126/scisignal.2004088
   PubMed Web of Science ®Google Scholar
• Williams CS, Bernard JK, Beckler MD, et al. ERBB4 is over-expressed in human colon cancer and enhances cellular transformation. Carcinogenesis. 2015;36(7):710–718.
   PubMed Web of Science ®Google Scholar
• Frampton GM, Fichtenholtz A, Otto GA, et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol. 2013;31(11):1023–1031. doi:10.1038/nbt.2696
   PubMed Web of Science ®Google Scholar
• Uzilov AV, Ding W, Fink MY, et al. Development and clinical application of an integrative genomic approach to personalized cancer therapy. Genome Med. 2016;8(1):62. doi:10.1186/s13073-016-0313-0
   PubMed Web of Science ®Google Scholar
• Romiti A, Roberto M, Marchetti P, et al. Study of histopathologic parameters to define the prognosis of Stage II colon cancer. Colorectal Dis. 2019;34(5):905–913. doi:10.1007/s00384-019-03279-1
   Web of Science ®Google Scholar
• Benson AB, Venook AP, Al-Hawary MM, et al. NCCN guidelines insights: colon cancer, Version 2.2018. J Natl Compr Canc Netw. 2018;16(4):359–369. doi:10.6004/jnccn.2018.0021
   PubMed Web of Science ®Google Scholar
• Szklarczyk D, Gable AL, Lyon D, et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2019;47(D1):D607–D613. doi:10.1093/nar/gky1131
   PubMed Web of Science ®Google Scholar
• American Cancer Society. Facts & figures 2019. Am Cancer Soc. 2019;4:e478.
   Google Scholar
• Dotan E, Cohen SJ. Challenges in the management of stage II colon cancer. Semin Oncol. 2011;38(4):511–520. doi:10.1053/j.seminoncol.2011.05.005
   PubMed Web of Science ®Google Scholar
• Gray R, Barnwell J, McConkey C, et al; Quasar Collaborative Group. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a Randomised Study. Lancet. 2007;370(9604):2020–2029. doi:10.1016/S0140-6736(07)61866-2
   PubMed Web of Science ®Google Scholar
• Compton C, Fenoglio-Preiser CM, Pettigrew N, Fielding LP. American joint committee on cancer prognostic factors consensus conference: colorectal Working Group. Cancer. 2000;88(7):1739–1757. doi:10.1002/(SICI)1097-0142(20000401)88:7<1739::AID-CNCR30>3.0.CO;2-T
   PubMed Web of Science ®Google Scholar
• Compton CC, Fielding LP, Burgart LJ, et al. Prognostic factors in colorectal cancer: College of American pathologists consensus statement 1999. Arch Pathol Lab Med. 2000;124(7):979–994. doi:10.5858/2000-124-0979-PFICC
   PubMed Web of Science ®Google Scholar
• André T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350(23):2343–2351. doi:10.1056/NEJMoa032709
   PubMed Web of Science ®Google Scholar
• Kuan TC, Chang SC, Lin JK, et al. Prognosticators of long-term outcomes of TNM stage II colorectal cancer: molecular patterns or clinicopathological features. World J Surg. 2019;43(12):3207–3215. doi:10.1007/s00268-019-05158-w
   PubMed Web of Science ®Google Scholar
• Miller JR, Hocking AM, Brown JD, Moon RT. Mechanism and function of signal transduction by the Wnt/beta-catenin and Wnt/Ca2+ pathways. Oncogene. 1999;18(55):7860–7872. doi:10.1038/sj.onc.1203245
   PubMed Web of Science ®Google Scholar
• Jou TS, Stewart DB, Stappert J, Nelson WJ, Marrs JA. Genetic and biochemical dissection of protein linkages in the cadherin-catenin complex. Proc Natl Acad Sci U S A. 1995;92(11):5067–5071. doi:10.1073/pnas.92.11.5067
   PubMed Web of Science ®Google Scholar
• Kawasaki Y, Senda T, Ishidate T, et al. Asef, a link between the tumor suppressor APC and G-protein signaling. Science. 2000;289(5482):1194–1197. doi:10.1126/science.289.5482.1194
   PubMed Web of Science ®Google Scholar
• Morrison EE, Wardleworth BN, Askham JM, et al. EB1, a protein which interacts with the APC tumour suppressor, is associated with the microtubule cytoskeleton throughout the cell cycle. Oncogene. 1998;17(26):3471–3477. doi:10.1038/sj.onc.1202247
   PubMed Web of Science ®Google Scholar
• Morin PJ, Vogelstein B, Kinzler KW. Apoptosis and APC in colorectal tumorigenesis. Proc Natl Acad Sci U S A. 1996;93(15):7950–7954. doi:10.1073/pnas.93.15.7950
   PubMed Web of Science ®Google Scholar
• He TC, Sparks AB, Rago C, et al. Identification of C-MYC as a target of the APC pathway. Science. 1998;281(5382):1509–1512. doi:10.1126/science.281.5382.1509
   PubMed Web of Science ®Google Scholar
• Tetsu O, McCormick F. Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature. 1999;398(6726):422–426. doi:10.1038/18884
   PubMed Web of Science ®Google Scholar
• Spruck CH, Strohmaier H, Sangfelt O, et al. HCDC4 gene mutations in endometrial cancer. Cancer Res. 2002;62(16):4535–4539.
   PubMed Web of Science ®Google Scholar
• Yeh CH, Bellon M, Nicot C. FBXW7: a critical tumor suppressor of human cancers. Mol Cancer. 2018;17(1):115. doi:10.1186/s12943-018-0857-2
   PubMed Web of Science ®Google Scholar
• Cao J, Ge MH, Ling ZQ. Fbxw7 tumor suppressor: a vital regulator contributes to human tumorigenesis. Medicine. 2016;95(7):e2496. doi:10.1097/MD.0000000000002496
   PubMed Web of Science ®Google Scholar
• Iwatsuki M, Mimori K, Ishii H, et al. Loss of FBXW7, a cell cycle regulating gene, in colorectal cancer: clinical significance. Int J Cancer. 2010;126(8):1828–1837. doi:10.1002/ijc.24879
   PubMed Web of Science ®Google Scholar
• Babaei-Jadidi R, Li N, Saadeddin A, et al. FBXW7 influences murine intestinal homeostasis and cancer, targeting Notch, Jun, and DEK for degradation. J Exp Med. 2011;208(2):295–312. doi:10.1084/jem.20100830
   PubMed Web of Science ®Google Scholar
• Kemp Z, Rowan A, Chambers W, et al. CDC4 mutations occur in a subset of colorectal cancers but are not predicted to cause loss of function and are not associated with chromosomal instability. Cancer Res. 2005;65(24):11361–11366. doi:10.1158/0008-5472.CAN-05-2565
   PubMed Web of Science ®Google Scholar
• Akhoondi S, Sun D, von der Lehr N, et al. FBXW7/HCDC4 is a general tumor suppressor in human cancer. Cancer Res. 2007;67(19):9006–9012. doi:10.1158/0008-5472.CAN-07-1320
   PubMed Web of Science ®Google Scholar
• Malapelle U, Pisapia P, Sgariglia R, et al. Less frequently mutated genes in colorectal cancer: evidences from next-generation sequencing of 653 routine cases. J Clin Pathol. 2016;69(9):767–771. doi:10.1136/jclinpath-2015-203403
   PubMed Web of Science ®Google Scholar
• Korphaisarn K, Morris VK, Overman MJ, et al. FBXW7 missense mutation: a novel negative prognostic factor in metastatic colorectal adenocarcinoma. Oncotarget. 2017;8(24):39268–39279. doi:10.18632/oncotarget.16848
   PubMedGoogle Scholar
• Bai J, Gao J, Mao Z, et al. Genetic mutations in human rectal cancers detected by targeted sequencing. J Hum Genet. 2015;60(10):589–596.
   PubMed Web of Science ®Google Scholar
• Jardim DL, Wheler JJ, Hess K, et al. FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with MTOR inhibitors. P PLoS One. 2014;9(2):e89388. doi:10.1371/journal.pone.0089388
   PubMed Web of Science ®Google Scholar
• Smith G, Carey FA, Beattie J, et al. Mutations in APC, Kirsten-Ras, and P53 - Alternative Genetic Pathways to Colorectal Cancer. Proc Natl Acad Sci U S A. 2002 Jul 9;99(14):9433–8
   Google Scholar
• Conlin A, Smith G, Carey FA, Wolf CR, Steele RJ. The prognostic significance of K-ras, p53, and APC mutations in colorectal carcinoma. Gut. 2005;54(9):1283–1286. doi:10.1136/gut.2005.066514
   PubMed Web of Science ®Google Scholar
• Datta J, Smith JJ, Chatila WK, et al. Coaltered Ras/B-Raf and TP53 is associated with extremes of survivorship and distinct patterns of metastasis in patients with metastatic colorectal cancer. Clin Cancer Res. 2020;26(5):1077–1085.
   PubMed Web of Science ®Google Scholar
• Esteller M. Epigenetic lesions causing genetic lesions in human cancer: promoter hypermethylation of DNA repair genes. Eur J Cancer. 2000;36(18):2294–2300. doi:10.1016/S0959-8049(00)00303-8
   PubMed Web of Science ®Google Scholar
• Kawakami K, Ruszkiewicz A, Bennett G, et al. DNA hypermethylation in the normal colonic mucosa of patients with colorectal cancer. Br J Cancer. 2006;94(4):593–598. doi:10.1038/sj.bjc.6602940
   PubMed Web of Science ®Google Scholar
• Weisenberger DJ, Siegmund KD, Campan M, et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet. 2006;38(7):787–793. doi:10.1038/ng1834
   PubMed Web of Science ®Google Scholar
• Arnold CN, Goel A, Compton C, et al. Evaluation of microsatellite instability, HMLH1 expression and HMLH1 promoter hypermethylation in defining the MSI phenotype of colorectal cancer. Cancer Biol Ther. 2004;3(1):73–78. doi:10.4161/cbt.3.1.590
   PubMed Web of Science ®Google Scholar
• Herman JG, Umar A, Polyak K, et al. Incidence and functional consequences of HMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci U S A. 1998;95(12):6870–6875. doi:10.1073/pnas.95.12.6870
   PubMed Web of Science ®Google Scholar
• Kuismanen SA, Holmberg MT, Salovaara R, de la Chapelle A, Peltomäki P. Genetic and epigenetic modification of MLH1 accounts for a major share of microsatellite-unstable colorectal cancers. Am J Pathol. 2000;156(5):1773–1779. doi:10.1016/S0002-9440(10)65048-1
   PubMed Web of Science ®Google Scholar
• de Vogel S, Bongaerts BW, Wouters KA, et al. Associations of dietary methyl donor intake with MLH1 promoter hypermethylation and related molecular phenotypes in sporadic colorectal cancer. Carcinogenesis. 2008;29(9):1765–1773. doi:10.1093/carcin/bgn074
   PubMed Web of Science ®Google Scholar
• Ogino S, Brahmandam M, Kawasaki T, Kirkner GJ, Loda M, Fuchs CS. Combined analysis of COX-2 and p53 expressions reveals synergistic inverse correlations with microsatellite instability and CpG island methylator phenotype in colorectal cancer. Neoplasia. 2006;8(6):458–464. doi:10.1593/neo.06247
   PubMed Web of Science ®Google Scholar
• Salahshor S, Kressner U, Pâhlman L, Glimelius B, Lindmark G, Lindblom A. Colorectal cancer with and without microsatellite instability involves different genes. Genes Chromosomes Cancer. 1999;26(3):247–252. doi:10.1002/(SICI)1098-2264(199911)26:3<247::AID-GCC9>3.0.CO;2-H
   PubMed Web of Science ®Google Scholar
• Samowitz WS, Albertsen H, Herrick J, et al. Evaluation of a large, population-based sample supports a CpG island methylator phenotype in colon cancer. Gastroenterology. 2005;129(3):837–845. doi:10.1053/j.gastro.2005.06.020
   PubMed Web of Science ®Google Scholar
• van Rijnsoever M, Grieu F, Elsaleh H, Joseph D, Iacopetta B. Characterisation of colorectal cancers showing hypermethylation at multiple CpG islands. Gut. 2002;51(6):797–802. doi:10.1136/gut.51.6.797
   PubMed Web of Science ®Google Scholar
• de Vogel S, Weijenberg MP, Herman JG, et al. MGMT and MLH1 promoter methylation versus APC, KRAS and BRAF gene mutations in colorectal cancer: indications for distinct pathways and sequence of events. Ann Oncol. 2009;20(7):1216–1222. doi:10.1093/annonc/mdn782
   PubMed Web of Science ®Google Scholar
• Tie J, Lipton L, Desai J, et al. KRAS mutation is associated with lung metastasis in patients with curatively resected colorectal cancer. Clin Cancer Res. 2011;17(5):1122–1130. doi:10.1158/1078-0432.CCR-10-1720
   PubMed Web of Science ®Google Scholar
• Huang D, Sun W, Zhou Y, et al. Mutations of key driver genes in colorectal cancer progression and metastasis. Cancer Metastasis Rev. 2018;37(1):173–187. doi:10.1007/s10555-017-9726-5
   PubMed Web of Science ®Google Scholar
• Schweiger T, Liebmann-Reindl S, Glueck O, et al. Mutational profile of colorectal cancer lung metastases and paired primary tumors by targeted next generation sequencing: implications on clinical outcome after surgery. J Thorac Dis. 2018;10(11):6147–6157. doi:10.21037/jtd.2018.10.72
   PubMed Web of Science ®Google Scholar
• Cai ZX, Tang XD, Gao HL, et al. APC, FBXW7, KRAS, PIK3CA, and TP53 gene mutations in human colorectal cancer tumors frequently detected by next-generation DNA sequencing [abstract]. J Mol Genet Med. 2014;8:4.
   Google Scholar
• Lugli A, Tzankov A, Zlobec I, Terracciano LM. Differential diagnostic and functional role of the multi-marker phenotype CDX2/CK20/CK7 in colorectal cancer stratified by mismatch repair status. Mod Pathol. 2008;21(11):1403–1412. doi:10.1038/modpathol.2008.117
   PubMed Web of Science ®Google Scholar
• Baba Y, Nosho K, Shima K, et al. Relationship of CDX2 loss with molecular features and prognosis in colorectal cancer. Clin Cancer Res. 2009;15(14):4665–4673. doi:10.1158/1078-0432.CCR-09-0401
   PubMed Web of Science ®Google Scholar
• Zlobec I, Bihl MP, Schwarb H, Terracciano L, Lugli A. Clinicopathological and protein characterization of BRAF- and K-RAS-mutated colorectal cancer and implications for prognosis. Int J Cancer. 2010;127(2):367–380. doi:10.1002/ijc.25042
   PubMed Web of Science ®Google Scholar
• Bae JM, Lee TH, Cho NY, Kim TY, Kang GH. Loss of CDX2 expression is associated with poor prognosis in colorectal cancer patients. World J Gastroenterol. 2015;21(5):1457–1467. doi:10.3748/wjg.v21.i5.1457
   PubMed Web of Science ®Google Scholar
• Kumar Y, Shukla N, Thacker G, et al. Ubiquitin ligase, Fbxw7, targets CDX2 for degradation via two phosphodegron motifs in a GSK3b-dependent manner. Mol Cancer Res. 2016;14(11):1097–1109. doi:10.1158/1541-7786.MCR-16-0138
   PubMed Web of Science ®Google Scholar
• Xu W, Zhu Y, Shen W, et al. Combination of CDX2 expression and T stage improves prognostic prediction of colorectal cancer. J Int Med Res. 2019;47(5):1829–1842. doi:10.1177/0300060518819620
   PubMed Web of Science ®Google Scholar
• Koopman M, Kortman GA, Mekenkamp L, et al. Deficient mismatch repair system in patients with sporadic advanced colorectal cancer. Br J Cancer. 2009;100(2):266–73.7. doi:10.1038/sj.bjc.6604867
   PubMed Web of Science ®Google Scholar
• Lothe RA, Peltomäki P, Meling GI, et al. Genomic instability in colorectal cancer: relationship to clinicopathological variables and family history. Cancer Res. 1993;53(24):5849–5852.
   PubMed Web of Science ®Google Scholar
• Thibodeau SN, Bren G, Schaid D. Microsatellite instability in cancer of the proximal colon. Science. 1993;260(5109):816–819. doi:10.1126/science.8484122
   PubMed Web of Science ®Google Scholar
• Jass JR, Barker M, Fraser L, et al. APC mutation and tumour budding in colorectal cancer. J Clin Pathol. 2003;56(1):69–73. doi:10.1136/jcp.56.1.69
   PubMed Web of Science ®Google Scholar
• Zlobec I, Lugli A. Invasive front of colorectal cancer: dynamic interface of pro-/anti-tumor factors. World J Gastroenterol. 2009;15(47):5898–5906. doi:10.3748/wjg.15.5898
   PubMed Web of Science ®Google Scholar
• Zlobec I, Lugli A. Epithelial mesenchymal transition and tumor budding in aggressive colorectal cancer: tumor budding as oncotarget. Oncotarget. 2010;1(7):651–661. doi:10.18632/oncotarget.199
   PubMedGoogle Scholar
• Koyama M, Morita T, Hashizume T, et al. Prognostic risk factors associated with recurrence after curative resection in patients with stage II colorectal cancer. Gan To Kagaku Ryoho. 2013;40(12):1650–1652.
   PubMedGoogle Scholar
• Nissan A, Stojadinovic A, Shia J, et al. Predictors of recurrence in patients with T2 and early T3, N0 adenocarcinoma of the rectum treated by surgery alone. J Clin Oncol. 2006;24(25):4078–4084. doi:10.1200/JCO.2006.06.2968
   PubMed Web of Science ®Google Scholar
• Fujita S, Shimoda T, Yoshimura K, Yamamoto S, Akasu T, Moriya Y. Prospective evaluation of prognostic factors in patients with colorectal cancer undergoing curative resection. J Surg Oncol. 2003;84(3):127–131. doi:10.1002/jso.10308
   PubMed Web of Science ®Google Scholar
• Quah HM, Chou JF, Gonen M, et al. Identification of patients with high-risk stage II colon cancer for adjuvant therapy. Dis Colon Rectum. 2008;51(5):503–507. doi:10.1007/s10350-008-9246-z
   PubMed Web of Science ®Google Scholar
• Huh JW, Kim HR, Kim YJ. Prognostic value of perineural invasion in patients with stage II colorectal cancer. Ann Surg Oncol. 2010;17(8):2066–2072. doi:10.1245/s10434-010-0982-7
   PubMed Web of Science ®Google Scholar
• Shinto E, Oki E, Shimokawa M, et al. A validation study for recurrence risk stratification of stage II colon cancer using the 55-gene classifier. Oncology. 2020;98(8):534–541. doi:10.1159/000506369
   PubMed Web of Science ®Google Scholar
• Des Guetz G, Schischmanoff O, Nicolas P, Perret GY, Morere JF, Uzzan B. Does microsatellite instability predict the efficacy of adjuvant chemotherapy in colorectal cancer? A systematic review with meta-analysis. Eur J Cancer. 2009;45(10):1890–1896. doi:10.1016/j.ejca.2009.04.018
   PubMed Web of Science ®Google Scholar
• Ghidini M, Personeni N, Bozzarelli S, et al. KRAS mutation in lung metastases from colorectal cancer: prognostic implications. Cancer Med. 2016;5(2):256–264. doi:10.1002/cam4.592
   PubMed Web of Science ®Google Scholar
• Li W, Qiu T, Guo L, Ying J, Zhou A. NGS-based oncogenic mutations analysis in advanced colorectal cancer patients improves targeted therapy prediction. Pathol Res Pract. 2019;215(3):483–489. doi:10.1016/j.prp.2018.12.037
   PubMed Web of Science ®Google Scholar
• Copija A, Waniczek D, Witkoś A, Walkiewicz K, Nowakowska-Zajdel E. Clinical significance and prognostic relevance of microsatellite instability in sporadic colorectal cancer patients. Int J Mol Sci. 2017;18(1):107. doi:10.3390/ijms18010107
   PubMed Web of Science ®Google Scholar
• Guinney J, Ferté C, Dry J, et al. Modeling RAS phenotype in colorectal cancer uncovers novel molecular traits of RAS dependency and improves prediction of response to targeted agents in patients. Clin Cancer Res. 2014;20(1):265–272. doi:10.1158/1078-0432.CCR-13-1943
   PubMed Web of Science ®Google Scholar
• Wertz IE, Kusam S, Lam C, et al. Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7. Nature. 2011;471(7336):110–114. doi:10.1038/nature09779
   PubMed Web of Science ®Google Scholar
• Tong J, Tan S, Zou F, Yu J, Zhang L. FBW7 mutations mediate resistance of colorectal cancer to targeted therapies by blocking Mcl-1 degradation. Oncogene. 2017;36(6):787–796. doi:10.1038/onc.2016.247
   PubMed Web of Science ®Google Scholar
• Lorenzi F, Babaei-Jadidi R, Sheard J, Spencer-Dene B, Nateri AS. Fbxw7-associated drug resistance is reversed by induction of terminal differentiation in murine intestinal organoid culture. Mol Ther Methods Clin Dev. 2016;3:16024. doi:10.1038/mtm.2016.24
   PubMed Web of Science ®Google Scholar
• Li N, Babaei-Jadidi R, Lorenzi F, et al. An FBXW7-ZEB2 axis links EMT and tumour microenvironment to promote colorectal cancer stem cells and chemoresistance. Oncogenesis. 2019;8(3):13. doi:10.1038/s41389-019-0125-3
   PubMedGoogle Scholar
• Ye M, Zhang Y, Zhang X, et al. Targeting FBW7 as a strategy to overcome resistance to targeted therapy in non–small cell lung cancer. Cancer Res. 2017;77(13):3527–3539. doi:10.1158/0008-5472.CAN-16-3470
   PubMed Web of Science ®Google Scholar
• Grim JE, Knoblaugh SE, Guthrie KA, et al. Fbw7 and P53 cooperatively suppress advanced and chromosomally unstable intestinal cancer. Mol Cell Biol. 2012;32(11):2160–2167. doi:10.1128/MCB.00305-12
   PubMed Web of Science ®Google Scholar
• Li MM, Datto M, Duncavage EJ, et al. Standards and guidelines for the interpretation and reporting of sequence variants in cancer: a joint consensus recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. J Mol Diagn. 2017;19(1):4–23. doi:10.1016/j.jmoldx.2016.10.002
   PubMed Web of Science ®Google Scholar